A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer

Oncology

Volumn 60, Issue 3, 2001, Pages 207-213

  Kakolyris, S ^a   Souglakos, J ^a   Kouroussis, C ^a   Androulakis, N ^a   Mavroudis, D ^a   Kalbakis, K ^a   Kotsakis, A ^a   Vardakis, N ^a   Koukourakis, M ^a   Romanos, J ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

5 FU; Colorectal cancer; CPT 11

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 17744365154     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055320     Document Type: Article

References (23)

1. Trends in cancer incidence and mortality
2. The chemotherapy of colon cancer can no longer be ignored
3. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. A randomized trial
4. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project
5. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
6. DNA topoisomerases - Enzymes that catalyze the breaking and rejoining of DNA
7. DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts
8. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
9. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
10. CPT-11 (irinotecan) in the treatment of colorectal cancer
11. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU
12. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
13. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
14. CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colorectal cancer
15. Dose-finding study of biweekly administration of irinotecan (CPT-11)/5-FU+6S-leucovorin (ILV) in colorectal cancer
16. Irinotecan in combination with leucovorin and 5-fluorouracil 48 hours continuous infusion: A phase I study with pharmacokinetic, DNA damage and to-poisomerase I/DNA complexes evaluation in chemotherapy naive metastatic colorectal cancer patients
17. Phase I and pharmacokinetic study of irinitecan, fluorouracil, and leucovorin in patients with advanced solid tumours
18. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
19. Characterization and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
20. A phase II multicenter trial of alternating cycles of irinotecan and 5-FU/LV in patients with previously untreated metastatic colorectal cancer
21. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
22. Phase II study of fluorouracil and its modulation in advanced colorectal cancer. A Southwest Oncology Group study